Titre : Thérapie comportementale

Thérapie comportementale : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Thérapie comportementale : Questions médicales les plus fréquentes", "headline": "Thérapie comportementale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Thérapie comportementale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-14", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Thérapie comportementale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Psychothérapie", "url": "https://questionsmedicales.fr/mesh/D011613", "about": { "@type": "MedicalCondition", "name": "Psychothérapie", "code": { "@type": "MedicalCode", "code": "D011613", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Thérapie de maitrise de la colère", "alternateName": "Anger Management Therapy", "url": "https://questionsmedicales.fr/mesh/D000067449", "about": { "@type": "MedicalCondition", "name": "Thérapie de maitrise de la colère", "code": { "@type": "MedicalCode", "code": "D000067449", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.087" } } }, { "@type": "MedicalWebPage", "name": "Analyse comportementale appliquée", "alternateName": "Applied Behavior Analysis", "url": "https://questionsmedicales.fr/mesh/D000072357", "about": { "@type": "MedicalCondition", "name": "Analyse comportementale appliquée", "code": { "@type": "MedicalCode", "code": "D000072357", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.131" } } }, { "@type": "MedicalWebPage", "name": "Thérapie aversive", "alternateName": "Aversive Therapy", "url": "https://questionsmedicales.fr/mesh/D001348", "about": { "@type": "MedicalCondition", "name": "Thérapie aversive", "code": { "@type": "MedicalCode", "code": "D001348", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.174" } } }, { "@type": "MedicalWebPage", "name": "Thérapie cognitive", "alternateName": "Cognitive Behavioral Therapy", "url": "https://questionsmedicales.fr/mesh/D015928", "about": { "@type": "MedicalCondition", "name": "Thérapie cognitive", "code": { "@type": "MedicalCode", "code": "D015928", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.350" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Thérapie d'acceptation et d'engagement", "alternateName": "Acceptance and Commitment Therapy", "url": "https://questionsmedicales.fr/mesh/D064869", "about": { "@type": "MedicalCondition", "name": "Thérapie d'acceptation et d'engagement", "code": { "@type": "MedicalCode", "code": "D064869", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.350.249" } } }, { "@type": "MedicalWebPage", "name": "Restructuration cognitive", "alternateName": "Cognitive Restructuring", "url": "https://questionsmedicales.fr/mesh/D000088686", "about": { "@type": "MedicalCondition", "name": "Restructuration cognitive", "code": { "@type": "MedicalCode", "code": "D000088686", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.350.375" } } }, { "@type": "MedicalWebPage", "name": "Pleine conscience", "alternateName": "Mindfulness", "url": "https://questionsmedicales.fr/mesh/D064866", "about": { "@type": "MedicalCondition", "name": "Pleine conscience", "code": { "@type": "MedicalCode", "code": "D064866", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.350.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Remédiation cognitive", "alternateName": "Cognitive Remediation", "url": "https://questionsmedicales.fr/mesh/D000072466", "about": { "@type": "MedicalCondition", "name": "Remédiation cognitive", "code": { "@type": "MedicalCode", "code": "D000072466", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.365" } } }, { "@type": "MedicalWebPage", "name": "Désensibilisation psychologique", "alternateName": "Desensitization, Psychologic", "url": "https://questionsmedicales.fr/mesh/D003887", "about": { "@type": "MedicalCondition", "name": "Désensibilisation psychologique", "code": { "@type": "MedicalCode", "code": "D003887", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Désensibilisation et reprogrammation par mouvements oculaires", "alternateName": "Eye Movement Desensitization Reprocessing", "url": "https://questionsmedicales.fr/mesh/D057169", "about": { "@type": "MedicalCondition", "name": "Désensibilisation et reprogrammation par mouvements oculaires", "code": { "@type": "MedicalCode", "code": "D057169", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506.162" } } }, { "@type": "MedicalWebPage", "name": "Thérapie implosive", "alternateName": "Implosive Therapy", "url": "https://questionsmedicales.fr/mesh/D007171", "about": { "@type": "MedicalCondition", "name": "Thérapie implosive", "code": { "@type": "MedicalCode", "code": "D007171", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506.325" } } }, { "@type": "MedicalWebPage", "name": "Thérapie par réalité virtuelle", "alternateName": "Virtual Reality Exposure Therapy", "url": "https://questionsmedicales.fr/mesh/D063367", "about": { "@type": "MedicalCondition", "name": "Thérapie par réalité virtuelle", "code": { "@type": "MedicalCode", "code": "D063367", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506.662" } } } ] }, { "@type": "MedicalWebPage", "name": "Thérapie comportementale dialectique", "alternateName": "Dialectical Behavior Therapy", "url": "https://questionsmedicales.fr/mesh/D000077252", "about": { "@type": "MedicalCondition", "name": "Thérapie comportementale dialectique", "code": { "@type": "MedicalCode", "code": "D000077252", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.628" } } }, { "@type": "MedicalWebPage", "name": "Thérapie par la relaxation", "alternateName": "Relaxation Therapy", "url": "https://questionsmedicales.fr/mesh/D012064", "about": { "@type": "MedicalCondition", "name": "Thérapie par la relaxation", "code": { "@type": "MedicalCode", "code": "D012064", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.750" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Méditation", "alternateName": "Meditation", "url": "https://questionsmedicales.fr/mesh/D019122", "about": { "@type": "MedicalCondition", "name": "Méditation", "code": { "@type": "MedicalCode", "code": "D019122", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.750.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Chronothérapie sur les phases de sommeil", "alternateName": "Sleep Phase Chronotherapy", "url": "https://questionsmedicales.fr/mesh/D055865", "about": { "@type": "MedicalCondition", "name": "Chronothérapie sur les phases de sommeil", "code": { "@type": "MedicalCode", "code": "D055865", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Thérapie comportementale", "alternateName": "Behavior Therapy", "code": { "@type": "MedicalCode", "code": "D001521", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Daniel F Gros", "url": "https://questionsmedicales.fr/author/Daniel%20F%20Gros", "affiliation": { "@type": "Organization", "name": "Mental Health Service, Ralph H. Johnson VA Healthcare System, Charleston, South Carolina, USA." } }, { "@type": "Person", "name": "Tanja van der Zweerde", "url": "https://questionsmedicales.fr/author/Tanja%20van%20der%20Zweerde", "affiliation": { "@type": "Organization", "name": "Department of Clinical Psychology, EMGO Institute for Health and Care Research, VU University, Van der Boechorststraat 7, Amsterdam 1081 BT, the Netherlands. Electronic address: t.vander.zweerde@vu.nl." } }, { "@type": "Person", "name": "Jaap Lancee", "url": "https://questionsmedicales.fr/author/Jaap%20Lancee", "affiliation": { "@type": "Organization", "name": "Department of Clinical Psychology, University of Amsterdam, Nieuwe Achtergracht 129, Amsterdam 1018 WS, the Netherlands; PsyQ Amsterdam, Amsterdam, the Netherlands." } }, { "@type": "Person", "name": "Annemieke van Straten", "url": "https://questionsmedicales.fr/author/Annemieke%20van%20Straten", "affiliation": { "@type": "Organization", "name": "Department of Clinical Psychology, EMGO Institute for Health and Care Research, VU University, Van der Boechorststraat 7, Amsterdam 1081 BT, the Netherlands." } }, { "@type": "Person", "name": "Shireen L Rizvi", "url": "https://questionsmedicales.fr/author/Shireen%20L%20Rizvi", "affiliation": { "@type": "Organization", "name": "Rutgers University. Electronic address: slrizvi@gsapp.rutgers.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Race and Ethnicity Differences in Disease Severity and Visual Field Progression Among Glaucoma Patients.", "datePublished": "2022-05-30", "url": "https://questionsmedicales.fr/article/35654121", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2022.05.023" } }, { "@type": "ScholarlyArticle", "name": "Comparing Static Perimetry Protocols of Central Field Testing among Patients with Glaucoma.", "datePublished": "2023-05-01", "url": "https://questionsmedicales.fr/article/37129640", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/OPX.0000000000002020" } }, { "@type": "ScholarlyArticle", "name": "Deep learning approaches to predict 10-2 visual field from wide-field swept-source optical coherence tomography en face images in glaucoma.", "datePublished": "2022-12-05", "url": "https://questionsmedicales.fr/article/36471039", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-25660-x" } }, { "@type": "ScholarlyArticle", "name": "Association of macular vessel density and ganglion cell complex thickness with central visual field progression in glaucoma.", "datePublished": "2023-11-22", "url": "https://questionsmedicales.fr/article/36150750", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bjo-2022-321870" } }, { "@type": "ScholarlyArticle", "name": "Survey on electronic visual field data transfer practices among Japan Glaucoma Society board members.", "datePublished": "2023-02-01", "url": "https://questionsmedicales.fr/article/36726104", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-023-02800-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Disciplines et activités comportementales", "item": "https://questionsmedicales.fr/mesh/D004191" }, { "@type": "ListItem", "position": 3, "name": "Psychothérapie", "item": "https://questionsmedicales.fr/mesh/D011613" }, { "@type": "ListItem", "position": 4, "name": "Thérapie comportementale", "item": "https://questionsmedicales.fr/mesh/D001521" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Thérapie comportementale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Thérapie comportementale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Thérapie comportementale", "description": "Comment diagnostiquer un besoin de thérapie comportementale ?\nQuels tests sont utilisés pour le diagnostic ?\nQui peut poser un diagnostic pour cette thérapie ?\nQuels critères sont utilisés pour le diagnostic ?\nLa thérapie comportementale est-elle adaptée à tous ?", "url": "https://questionsmedicales.fr/mesh/D001521?mesh_terms=Visual+Field+Tests&page=6#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Thérapie comportementale", "description": "Quels symptômes indiquent un besoin de thérapie comportementale ?\nComment les symptômes varient-ils selon les individus ?\nLes symptômes physiques sont-ils liés à la thérapie comportementale ?\nLes symptômes peuvent-ils s'aggraver sans traitement ?\nQuels sont les signes d'amélioration avec la thérapie ?", "url": "https://questionsmedicales.fr/mesh/D001521?mesh_terms=Visual+Field+Tests&page=6#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Thérapie comportementale", "description": "Comment prévenir les troubles nécessitant une thérapie comportementale ?\nLes programmes scolaires peuvent-ils aider à la prévention ?\nQuels rôles jouent les parents dans la prévention ?\nLa prévention est-elle possible à l'âge adulte ?\nLes groupes de soutien peuvent-ils aider à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D001521?mesh_terms=Visual+Field+Tests&page=6#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Thérapie comportementale", "description": "Quelles techniques sont utilisées en thérapie comportementale ?\nCombien de séances sont généralement nécessaires ?\nLa thérapie comportementale peut-elle être combinée avec d'autres traitements ?\nQuels sont les objectifs principaux de cette thérapie ?\nLa thérapie comportementale est-elle efficace pour les enfants ?", "url": "https://questionsmedicales.fr/mesh/D001521?mesh_terms=Visual+Field+Tests&page=6#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Thérapie comportementale", "description": "Quelles complications peuvent survenir sans traitement ?\nLa thérapie comportementale peut-elle entraîner des effets secondaires ?\nQuels risques de rechute existent après la thérapie ?\nLes complications psychologiques peuvent-elles affecter la santé physique ?\nComment minimiser les complications après la thérapie ?", "url": "https://questionsmedicales.fr/mesh/D001521?mesh_terms=Visual+Field+Tests&page=6#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Thérapie comportementale", "description": "Quels facteurs augmentent le risque de troubles comportementaux ?\nL'environnement familial influence-t-il les comportements ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe manque de soutien social est-il un facteur de risque ?\nLes événements de vie stressants augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D001521?mesh_terms=Visual+Field+Tests&page=6#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un besoin de thérapie comportementale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel évalue les comportements problématiques et leur impact sur la vie quotidienne." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des questionnaires et des entretiens cliniques sont souvent utilisés pour évaluer les comportements." } }, { "@type": "Question", "name": "Qui peut poser un diagnostic pour cette thérapie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Un psychologue, un psychiatre ou un thérapeute qualifié peut poser ce diagnostic." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la fréquence, l'intensité et l'impact des comportements sur la vie." } }, { "@type": "Question", "name": "La thérapie comportementale est-elle adaptée à tous ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle est efficace pour de nombreux troubles, mais un diagnostic précis est essentiel." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin de thérapie comportementale ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des comportements compulsifs, des phobies ou des troubles d'anxiété peuvent indiquer ce besoin." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les individus ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent varier en intensité et en type selon les expériences personnelles." } }, { "@type": "Question", "name": "Les symptômes physiques sont-ils liés à la thérapie comportementale ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes physiques comme des palpitations peuvent accompagner des troubles psychologiques." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver sans traitement ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les symptômes peuvent s'intensifier et affecter la qualité de vie." } }, { "@type": "Question", "name": "Quels sont les signes d'amélioration avec la thérapie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une réduction des comportements problématiques et une meilleure gestion des émotions sont des signes." } }, { "@type": "Question", "name": "Comment prévenir les troubles nécessitant une thérapie comportementale ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par l'éducation émotionnelle et le développement de compétences sociales dès le jeune âge." } }, { "@type": "Question", "name": "Les programmes scolaires peuvent-ils aider à la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des programmes de sensibilisation et de gestion des émotions dans les écoles peuvent être bénéfiques." } }, { "@type": "Question", "name": "Quels rôles jouent les parents dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les parents peuvent enseigner des stratégies de gestion du stress et des comportements positifs à leurs enfants." } }, { "@type": "Question", "name": "La prévention est-elle possible à l'âge adulte ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques de gestion du stress et de résolution de problèmes peuvent prévenir l'apparition de troubles." } }, { "@type": "Question", "name": "Les groupes de soutien peuvent-ils aider à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les groupes de soutien offrent un espace pour partager des expériences et apprendre des stratégies de prévention." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées en thérapie comportementale ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme le conditionnement opérant, l'exposition et la restructuration cognitive sont courantes." } }, { "@type": "Question", "name": "Combien de séances sont généralement nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le nombre de séances varie, mais 10 à 20 séances sont souvent recommandées pour des résultats significatifs." } }, { "@type": "Question", "name": "La thérapie comportementale peut-elle être combinée avec d'autres traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est souvent combinée avec des médicaments ou d'autres formes de thérapie pour une efficacité accrue." } }, { "@type": "Question", "name": "Quels sont les objectifs principaux de cette thérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les objectifs incluent la modification des comportements inadaptés et l'amélioration des compétences d'adaptation." } }, { "@type": "Question", "name": "La thérapie comportementale est-elle efficace pour les enfants ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est souvent utilisée pour traiter des troubles chez les enfants, comme l'anxiété et les phobies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir sans traitement ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Sans traitement, les troubles peuvent s'aggraver, entraînant des problèmes relationnels et professionnels." } }, { "@type": "Question", "name": "La thérapie comportementale peut-elle entraîner des effets secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Généralement, elle n'a pas d'effets secondaires physiques, mais des émotions intenses peuvent survenir." } }, { "@type": "Question", "name": "Quels risques de rechute existent après la thérapie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des rechutes peuvent survenir si les compétences acquises ne sont pas pratiquées régulièrement." } }, { "@type": "Question", "name": "Les complications psychologiques peuvent-elles affecter la santé physique ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles psychologiques non traités peuvent entraîner des problèmes de santé physique, comme des maladies cardiaques." } }, { "@type": "Question", "name": "Comment minimiser les complications après la thérapie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La pratique continue des compétences apprises et le soutien social aident à minimiser les complications." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de troubles comportementaux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme le stress, l'hérédité et des événements traumatiques augmentent le risque." } }, { "@type": "Question", "name": "L'environnement familial influence-t-il les comportements ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un environnement familial instable ou conflictuel peut contribuer au développement de troubles." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de troubles mentaux dans la famille peuvent augmenter le risque de troubles comportementaux." } }, { "@type": "Question", "name": "Le manque de soutien social est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un manque de soutien social peut exacerber les troubles et rendre la gestion plus difficile." } }, { "@type": "Question", "name": "Les événements de vie stressants augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des événements comme un divorce ou la perte d'un emploi peuvent déclencher des troubles comportementaux." } } ] } ] }

Sous-catégories

16 au total

Sources (10000 au total)

Race and Ethnicity Differences in Disease Severity and Visual Field Progression Among Glaucoma Patients.

Investigate associations of race/ethnicity and preferred language with baseline glaucoma severity, VF test frequency and disease progression.... Retrospective cohort study.... Patients receiving VF testing at a tertiary eyecare center between 1998 and 2020 with self-identified race, ethnicity and preferred language were included. Outcome measures were VF MD and age at first... Among 29,891 patients with VF measurements between 1998 and 2020, 55.1% were female, 71.0% self-identified as White/Caucasian, 14.0% as Black/African American, 7.4% as Asian and 6.4% as Hispanic, and ... Black, Asian and Hispanic patients had greater baseline severity vs. Whites. Unlike other groups, Black patients had a lower VF frequency vs. Whites and greater VF progression. Disparities in baseline...

Comparing Static Perimetry Protocols of Central Field Testing among Patients with Glaucoma.

On comparing the Humphrey Field Analyzer (HFA) 24-2C Faster, which tests 10 additional points in the central field, with the 24-2 Swedish Interactive Thresholding Algorithm (SITA) Standard for detecti... This study aimed to compare the HFA 24-2C Faster with the 24-2 SITA Standard and 10-2 among patients with glaucoma for the number of defective central points, global indices, and testing time.... Sixty eyes of 60 patients with glaucoma and glaucomatous visual field defects on the 24-2 SITA Standard algorithm underwent the 24-2C Faster and 10-2 field tests. The number of central points detected... The 24-2C Faster, on average, detected 5.5 defective points more on the total deviation plot and 2 defective points more on the pattern deviation plot than the 24-2 SITA Standard in central 10°. The 1... Our study demonstrates that the HFA 24-2C Faster may be used for the initial evaluation of the visual field in glaucoma with the added advantage of a shorter testing time compared with the 24-2 SITA S...

Association of macular vessel density and ganglion cell complex thickness with central visual field progression in glaucoma.

To evaluate the association of macular vessel density (VD) and ganglion cell complex (GCC) thickness with 10-2 central visual field (CVF) progression in glaucoma.... In this retrospective cohort study, patients with glaucoma from Diagnostic Innovation in Glaucoma Study with≥five 10-2 visual field (VF) tests and 3-year follow-up before optical coherence tomography ... From 238 eyes (141 patients), 25 eyes (11%) of 16 patients were CVF progressors. In the multivariable analysis of the association between OCT/OCTA parameters and past rate of 10-2 CVF worsening, lower... Lower macular VD and GCC were associated with faster worsening of CVF, and lower macular VD was associated with increased odds of CVF progression. Assessment of macular OCT and OCTA may help detect gl...

Survey on electronic visual field data transfer practices among Japan Glaucoma Society board members.

Visual field (VF) testing in combination with a specialized VF analysis software is critical for characterizing and monitoring visual loss in glaucoma. Although performing glaucoma progression analysi... An internet survey of daily practice patterns regarding electronic VF data transfer at the time of glaucoma referrals (referring/referred) was sent to all 50 JGS board members. The survey consisted wi... The respondents included 33 university hospital ophthalmologists (66%) (Q1), and those scattered throughout Japan (Q2). All respondents used Humphrey Visual Filed Analyzer (HFA) (Q3) and at least one ... An internet survey showed that 80% of the JGS board members were not actively transferring VF data mainly because of the absence of a system in place at institutions for sending and receiving data, al...

Driving and exceptional cases: Supporting relicensing evaluation in patients whose visual fields fail to meet standards.

The UK Driver and Vehicle Licensing Agency's (DVLA) visual field criteria mean that homonymous defects close to fixation are not usually acceptable for driving. Here, we illustrate cases where patient... Clinical assessment of two patients with homonymous loss: a 62-year-old man (PWT) with a dense left upper homonymous quadrantanopia secondary to a right occipital lobe stroke and a 48-year-old woman (... PWT's Esterman test showed a significant central defect failing to meet the standard. His subsequent ophthalmic examination was otherwise unremarkable with excellent visual functions. Clinical evidenc... Conventional visual field tests are not necessarily predictive of real-world driving performance, with drivers' adaptive strategies not being accommodated. In the UK, individuals with visual field los...

The Association Between Regional Macula Vessel Density and Central Visual Field Damage in Advanced Glaucoma Eyes.

Both macular superficial vessel density and ganglion cell complex (GCC) thickness measurement are significantly associated with regional and global 10-degree central visual field (VF) sensitivity in a... The purpose of this study was to evaluate the regional and global structure-function relationships between macular vessel density (MVD) assessed by optical coherence tomography angiography (OCTA) and ... Macular OCTA and 10-2 VF sensitivity of 44 patients [mean deviation (MD) <-10 dB] were evaluated. Regional and global VF mean sensitivity (MS) was calculated from total deviation plots. Superficial an... Lower MS was significantly associated with a reduction in superficial MVD and GCC in each region of both scan sizes for both maps. Associations were weaker in the individual sectors of the whole image... Given a stronger MVD-central 10-degree VF association compared with GCC, as well as stronger GCC-central 5-degree VF association compared with MVD, MVD and GCC are complementary measurements in eyes w...

Prediction of visual field defects from macular optical coherence tomography in glaucoma using cluster analysis.

To assess the accuracy of cluster analysis-based models in predicting visual field (VF) defects from macular ganglion cell-inner plexiform layer (GCIPL) measurements in glaucomatous and healthy cohort... GCIPL measurements were extracted from posterior pole optical coherence tomography (OCT), from locations corresponding to central VF test grids. Models incorporating cluster analysis methods and corre... Clustered models demonstrated globally low sensitivity, but high specificity in the glaucoma cohort (0.28-0.53 and 0.77-0.91, respectively), and high specificity in the healthy cohort (0.91-0.98). Clu... Cluster analysis-based models incorporating age correction and holistic consideration of fovea to optic disc tilt demonstrated superior performance in predicting VF results to pointwise methods in bot...

Measures of multiple deprivation and visual field loss in glaucoma clinics in England: lessons from big data.

To examine the association between multiple deprivation with late diagnosis and rapid worsening of glaucoma in patients in English hospital eye services (HES).... 602,439 visual fields (VFs) were extracted from five regionally different glaucoma clinics in England. Mean Deviation (MD) worse than -12 dB was used as a surrogate definition for advanced VF loss at ... There was an association between IMD and advanced VF loss at diagnosis in 44,956 patients with 18% (293/1608) and 11% (771/6929) in the most and least deprived IMD decile, respectively. Age-corrected ... Large-scale VF data from clinics indicates that glaucoma severity at presentation to English HES is associated with levels of multiple deprivation. We found no evidence to suggest likelihood of having...

Structural and vascular changes in glaucoma with single-hemifield defect: predictors of opposite hemifield visual field progression.

To investigate longitudinal changes in optic nerve head (ONH) superficial vessel density (VD), macular VD, circumpapillary retinal nerve fiber layer (RNFL) thickness, and macular ganglion cell-inner p... This retrospective observational study included 61 POAG eyes with VF defect confined to a single hemifield monitored over a mean follow-up time of 2.7 years. Development of VF defect in opposite hemif... Among 61 eyes, 17 eyes (27.9%) were classified as "conversion" and 44 eyes (72.1%) were classified as "non-conversion" groups. The conversion group exhibited significantly greater rates of both VD and... Monitoring progressive changes in VD and structural parameters effectively predict future VF defect in the opposite hemifields of POAG eyes with single-hemifield defects....